Patent ID: 7972797
Filing Date: 2011-07-05
Classification: A61K,A61P,C07K

Abstract:
1. A method for detecting aberrant expression of a 103 polypeptide in a subject, comprising: a) contacting an isolated sample of cells or body fluid from said subject with a monoclonal antibody produced by: (i) hybridoma clone M15 3F7.3 (ATCC™ No. PTA-593); (ii) hybridoma clone M15 203.1 (ATCC™ No. PTA-591); (iii) hybridoma clone M15 10F7.1 (ATCC™ No. PTA-592); (iv) hybridoma clone M15 1B4.1 (ATCC™ No. PTA-588); (v) hybridoma clone M15 9F11.1 (ATCC™ No. PTA-590); or (vi) hybridoma clone M15 5A16.1 (ATCC™ No. PTA-587); or an antigen binding fragment thereof; and b) measuring the level of the 103 polypeptide in said sample by detecting binding of the antibody or antigen binding fragment to the polypeptide, wherein an increase or decrease in the 103 polypeptide level in said sample relative to a standard level of 103 polypeptide indicates aberrant expression of said 103 polypeptide in said subject.